Prenatal Genetic Screening

What is NIPT?

Non-Invasive Prenatal Testing (NIPT) analyzes cell-free DNA circulating in maternal blood during pregnancy.

How NIPT works

A portion of cfDNA in maternal circulation is placental in origin and carries pregnancy-related genetic information. Advanced genomic analysis can provide information about the chance of certain chromosomal anomalies.

When can NIPT be done?

From gestational weeks when adequate fetal fraction can be obtained. Timing depends on gestational age, clinical context, and the selected panel — typically from week 10 for NIPTGEN PLUS.

Clinical decision

Screening is not diagnosis. Results are interpreted by the patient’s clinician with other pregnancy findings.

What is Fetal Fraction?

Fetal fraction refers to the proportion of placental cfDNA within the total cell-free DNA in maternal blood.

Adequate fetal fraction is one of the important quality parameters for reliable NIPT analysis.

In some cases, a new blood sample may be required due to low fetal fraction.

How NIPT Works
NIPT process infographic: maternal blood, cfDNA, DNA isolation, NGS, bioinformatics, and report
NIPT

The process

01

Clinical assessment

The clinician selects the appropriate prenatal screening option.

02

Blood sample

A maternal blood sample is collected under required conditions.

03

Genomic analysis

cfDNA is evaluated with advanced genomic methods.

04

Quality control

Analysis data and quality parameters including fetal fraction are reviewed.

05

Reporting

Results are prepared as a structured genetic screening report.

06

Clinical review

The clinician interprets results with clinical information and other findings.